2023
Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
DUNDR, Pavel, Michaela BÁRTŮ, Tjalling BOSSE, Quang Hiep BUI, David CIBULA et. al.Základní údaje
Originální název
Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
Autoři
DUNDR, Pavel (203 Česká republika, garant), Michaela BÁRTŮ (203 Česká republika), Tjalling BOSSE, Quang Hiep BUI, David CIBULA (203 Česká republika), Jana DROZENOVÁ (203 Česká republika), Pavel FABIAN (203 Česká republika), Oluwole FADARE, Jitka HAUSNEROVÁ (203 Česká republika, domácí), Jan HOJNÝ (203 Česká republika), Nikola HÁJKOVÁ (203 Česká republika), Radek JAKŠA (203 Česká republika), Jan LACO (203 Česká republika), Sigurd F. LAX, Radoslav MATĚJ (203 Česká republika), Gábor MÉHES, Romana MICHÁLKOVÁ (203 Česká republika), Adam ŠAFANDA (203 Česká republika), Kristýna NĚMEJCOVÁ (203 Česká republika), Naveena SINGH, Simona STOLNICU, Marián ŠVAJDLER (203 Česká republika), Tomáš ZIMA (203 Česká republika), Ivana STRUŽINSKÁ (203 Česká republika) a W Glenn MCCLUGGAGE
Vydání
Modern Pathology, NEW YORK, ELSEVIER SCIENCE INC, 2023, 0893-3952
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30109 Pathology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 7.500 v roce 2022
Kód RIV
RIV/00216224:14110/23:00130743
Organizační jednotka
Lékařská fakulta
UT WoS
000982550100001
Klíčová slova anglicky
borderline; diagnostic agreement; mucinous tumors; next-generation sequencing; ovary; therapeutic targets
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 7. 2023 10:41, Mgr. Tereza Miškechová
Anotace
V originále
Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor. After excluding 1 outlier participant, there was a moderate agreement in diagnosing the 124 cases when divided into 3 categories (κ = 0.524, for mucinous cystadenoma vs MBT vs MC). A perfect agreement for the distinction between mucinous cystadenoma/MBT as a combined category and MC was found in only 36.3% of the cases. Differentiating between MBTs and MCs with expansile invasion was particularly problematic. After a reclassification of the tumors into near-consensus diagnostic categories on the basis of the initial participant results, a comparison of molecular findings between the MBT and MC groups did not show major and unequivocal differences between MBTs and MCs or between MCs with expansile vs infiltrative pattern of invasion. In contrast, HER2 overexpression or amplification was found only in 5.3% of MBTs and in 35.3% of all MCs and in 45% of MCs with expansile invasion. Overall, HER2 alterations, including mutations, were found in 42.2% of MCs. KRAS mutations were found in 65.5% and PIK3CA mutations in 6% of MCs. In summary, although the diagnostic criteria are well-described, diagnostic agreement among our large group of experienced gynecologic pathologists was only moderate. Diagnostic categories showed a molecular overlap. Nonetheless, molecular profiling may prove to be therapeutically beneficial in advanced-stage, recurrent, or metastatic MCs.
Návaznosti
90125, velká výzkumná infrastruktura |
|